CNTB Stock Analysis: Buy, Sell, or Hold?
CNTB - Connect Biopharma Holdings Limited Ordinary Shares
$2.09
0.10 (5.03%)
▲
5d:
+1.46%
30d:
-11.44%
90d:
-29.15%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When CNTB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CNTB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CNTB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CNTB is currently trading at $2.09, which is considered slightly low relative to its 30-day fair value range of $2.07 to $2.36.
Technical Outlook: Technically, CNTB is in a downtrend. Immediate support is located at $1.93, while resistance sits at $2.29. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: CNTB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.07 (+238.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CNTB is in a downtrend. Immediate support is located at $1.93, while resistance sits at $2.29. The stock is showing strong short-term momentum, up 5.0% recently.
Market Sentiment: CNTB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.07 (+238.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.07 -
$2.36
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.0%)
- BULLISH: Trading 238.3% below Wall St target ($7.07)
Trading Range Analysis
30-Day Trading Range
$2.07 -
$2.36
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.93
Resistance Level
$2.29
Current Trend
Downtrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.00
Wall Street Target
$7.07
(+238.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 24, 2026 9:16 AM ET
Data refreshes hourly during market hours. Next update: 10:16 AM
Data refreshes hourly during market hours. Next update: 10:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTB showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
James Huang
BUY
1160000 shares
2026-03-31
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
